Department of Nuclear Medicine, Centre Henri-Becquerel, Rue d'Amiens, 76038, Rouen Cedex, France.
QuantIF-LITIS (EA [Equipe d'Accueil] 4108), Faculty of Medicine, University of Rouen, Rouen, France.
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2034-2041. doi: 10.1007/s00259-017-3776-3. Epub 2017 Jul 21.
We examined whether FDG PET can be used to predict outcome in patients with lymphoblastic lymphoma (LL).
This was a retrospective post hoc analysis of data from the GRAAL-LYSA LL03 trial, in which the treatment of LL using an adapted paediatric-like acute lymphoblastic leukaemia protocol was evaluated. PET data acquired at baseline and after induction were analysed. Maximum standardized uptake values (SUV), total metabolic tumour volume and total lesion glycolysis were measured at baseline. The relative changes in SUV from baseline (ΔSUV) and the Deauville score were determined after induction.
The population analysed comprised 36 patients with T-type LL. SUV using a cut-off value of ≤8.76 vs. >8.76 was predictive of 3-year event-free survival (31.6% vs. 80.4%; p = 0.013) and overall survival (35.0% vs. 83.7%; p = 0.028). ΔSUV using a cut-off value of ≤80% vs. >80% tended also to be predictive of 3-year event-free survival (40.0% vs. 76.0%; p = 0.054) and overall survival (49.2% vs. 85.6%; p = 0.085). Total metabolic tumour volume, baseline total lesion glycolysis and response according to the Deauville score were not predictive of outcome.
A low initial SUV was predictive of worse outcomes in our series of patients with T-type LL. Although relatively few patients were included, the study also suggested that ΔSUV may be useful for predicting therapeutic efficacy.
我们研究了氟脱氧葡萄糖正电子发射断层扫描（FDG PET）是否可用于预测淋巴母细胞淋巴瘤（LL）患者的结局。
这是 GRAAL-LYSA LL03 试验数据的回顾性事后分析，该试验评估了采用改良儿科样急性淋巴细胞白血病方案治疗 LL 的效果。分析了基线和诱导后获得的 PET 数据。在基线时测量最大标准化摄取值（SUV）、总代谢肿瘤体积和总病变糖酵解。确定诱导后 SUV 的基线相对变化（ΔSUV）和 Deauville 评分。
分析人群包括 36 例 T 型 LL 患者。SUV 使用截断值≤8.76 与＞8.76 预测 3 年无事件生存率（31.6%与 80.4%；p=0.013）和总生存率（35.0%与 83.7%；p=0.028）。ΔSUV 使用截断值≤80%与＞80%也倾向于预测 3 年无事件生存率（40.0%与 76.0%；p=0.054）和总生存率（49.2%与 85.6%；p=0.085）。基线总代谢肿瘤体积、总病变糖酵解和 Deauville 评分的反应均不能预测结局。
在我们的 T 型 LL 患者系列中，初始 SUV 低与结局较差相关。尽管纳入的患者相对较少，但该研究还表明，ΔSUV 可能有助于预测治疗效果。
